Clinical bottom line
Serum soluble CD137 (sCD137) is an emerging biomarker reflecting immune activation and fibrotic progression in chronic liver diseases. Preliminary evidence suggests that elevated sCD137 levels correlate with liver cirrhosis severity and may have prognostic value in chronic hepatitis B (CHB) management. While most data derive from hepatitis C and alcohol-related liver disease cohorts, the immunological role of CD137 in T cell activation supports its potential utility in CHB. However, clinical adoption requires further validation in well-characterized CHB populations to define diagnostic thresholds, prognostic accuracy, and response to antiviral therapy.
What the evidence shows
CD137 (4-1BB) is a costimulatory receptor expressed on activated T cells, playing a critical role in modulating immune responses. Its soluble form, sCD137, is released into circulation and can be measured in serum. Recent studies have identified sCD137 as a novel serum marker associated with liver cirrhosis severity in patients with hepatitis C virus (HCV) infection and alcohol-associated liver disease (AALD) [1]. These studies demonstrated that sCD137 levels increase with advancing fibrosis and cirrhosis, reflecting ongoing immune activation and fibrogenesis.
Although direct evidence in CHB is limited, the immunopathogenesis of CHB involves chronic immune activation and T cell exhaustion, processes in which CD137 signaling is implicated. Elevated sCD137 may therefore serve as a surrogate for immune activation status and fibrotic burden in CHB. This biomarker could complement existing tools by providing dynamic information on immune-mediated liver injury beyond static fibrosis staging.
The reviewed literature highlights that sCD137 correlates with established fibrosis markers and clinical parameters of liver dysfunction. For example, higher sCD137 levels were associated with worse Child-Pugh scores and portal hypertension indicators in cirrhotic patients [3]. These findings suggest sCD137 might stratify patients at higher risk of progression or decompensation.
Caveats and uncertainty
Current evidence for sCD137 as a biomarker in CHB is largely extrapolated from studies in HCV and AALD cohorts, limiting direct applicability. The reviewed studies employed heterogeneous patient populations and assay methods, with variable cutoffs and limited longitudinal data. The specificity of sCD137 for liver disease versus systemic immune activation remains unclear, as CD137 is involved in multiple inflammatory conditions.
Furthermore, the cross-sectional design of most analyses precludes assessment of sCD137 dynamics during antiviral therapy or disease remission. Its prognostic value for clinical outcomes such as hepatic decompensation, hepatocellular carcinoma development, or treatment response in CHB is unproven. Potential confounders including co-infections, comorbidities, and immunomodulatory medications were not consistently controlled.
Standardization of sCD137 measurement and validation in large, prospective CHB cohorts are necessary to establish clinical thresholds and predictive performance. Integration with existing noninvasive fibrosis markers and immune profiling may enhance interpretability but requires systematic evaluation.
How this may change practice
If validated, serum sCD137 could become a useful adjunct biomarker in CHB management by providing insights into immune activation status and fibrotic progression. It may aid in risk stratification, identifying patients who warrant closer monitoring or early therapeutic intervention. Additionally, sCD137 could serve as a pharmacodynamic marker to gauge immunomodulatory treatment effects or predict antiviral therapy outcomes.
In clinical practice, sCD137 measurement might complement existing fibrosis assessment tools such as transient elastography and serum fibrosis panels, particularly when these yield indeterminate results. It may also help differentiate active immune-mediated liver injury from quiescent disease phases.
However, given current limitations, routine use of sCD137 in CHB is premature. Clinicians should await further evidence from prospective studies before incorporating this biomarker into decision-making algorithms. Meanwhile, sCD137 remains a promising candidate warranting further translational and clinical research.